ETFs positioned on GSK plc

Name YTD change Weight AuM
+13.45%-.--% 24,432 M€
+13.46%-.--% 750 M€
-.--%-.--% 22 M€
+11.00%-.--% 44 M€
+5.97%-.--% 49 M€
+1.63%-.--% 51 M€
+12.33%-.--% 66 M€
+8.93%-.--% 75 M€
+13.12%-.--% 6,576 M€
+11.80%-.--% 274 M€
+10.24%-.--% 122 M€
+11.35%-.--% 1,193 M€
+15.24%-.--% 1,674 M€
+10.41%9.81% 28 M€
+7.56%8.02% 9 M€
+10.39%7.14% 987 M€
-.--%7.14% 987 M€
+10.34%6.59% 12 M€
+4.33%5.94% 1,024 M€
+13.20%5.9% 38 M€
+10.16%5.9% 90 M€
+8.38%5.86% 56 M€
+0.80%5.75% 12 M€
+2.37%5.75% 820 M€
+5.44%5.14% 58 M€
+8.36%5.09% 11 M€
+5.03%5.09% 667 M€
+12.37%5.02% 19 M€
+7.77%4.94% 9 M€
+5.89%4.92% 1,018 M€
0.00%4.18% 8 M€
+57.31%4.1% 215 M€
+15.21%4.03% 1,807 M€
+12.99%3.8% 2,529 M€
+10.49%3.62% 50 M€
+8.57%3.57% 106 M€
+7.73%3.57% 19 M€
+8.96%3.57% 147 M€
+12.25%3.57% 1,166 M€
+12.53%3.48% 935 M€
+8.63%3.36% 1,190 M€
-.--%3.36% 1,190 M€
+14.47%3.33% 114 M€
+11.81%3.33% 265 M€
+12.87%3.31% 1,211 M€
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
18.90GBP
Average target price
21.69GBP
Spread / Average Target
+14.72%

Quarterly revenue - Rate of surprise